These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24853074)

  • 1. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
    Kim CA; Price-Hiller J; Chu QS; Tankel K; Hennig R; Sawyer MB; Spratlin JL
    Invest New Drugs; 2014 Oct; 32(5):1036-45. PubMed ID: 24853074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
    Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
    BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
    Shah RR
    Drug Saf; 2017 May; 40(5):373-386. PubMed ID: 28181126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases.
    Furubayashi N; Negishi T; Iwai H; Nagase K; Nakamura M
    Mol Clin Oncol; 2017 Aug; 7(2):281-284. PubMed ID: 28781802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
    Padhy BM; Shanmugam SP; Gupta YK; Goyal A
    Br J Clin Pharmacol; 2011 May; 71(5):777-9. PubMed ID: 21480952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine.
    Chen YH; Huang CH
    Clin Breast Cancer; 2012 Jun; 12(3):222-5. PubMed ID: 22424944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
    Sharief U; Perry DJ
    Clin Colorectal Cancer; 2009 Jul; 8(3):163-5. PubMed ID: 19632931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.
    Ryan SA; Maceneaney P; O'Reilly SP; Moylan EJ; Power DG
    Med Oncol; 2012 Jun; 29(2):1287-91. PubMed ID: 21390516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior reversible leukoencephalopathy syndrome associated with pazopanib.
    Foerster R; Welzel T; Debus J; Gruellich C; Jaeger D; Potthoff K
    Case Rep Oncol; 2013 Jan; 6(1):204-8. PubMed ID: 23626562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical spectrum of reversible posterior leukoencephalopathy syndrome.
    Lee VH; Wijdicks EF; Manno EM; Rabinstein AA
    Arch Neurol; 2008 Feb; 65(2):205-10. PubMed ID: 18268188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced posterior reversible encephalopathy syndrome.
    Prescrire Int; 2017 Apr; 26(181):98-101. PubMed ID: 30730661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reversible posterior leukoencephalopathy syndrome in a patient presenting granulomatosis with polyangiitis].
    Chaput L; Rabot N; Limousin N; Cottier JP; Lioger B; Samimi M
    Ann Dermatol Venereol; 2017 Feb; 144(2):113-120. PubMed ID: 27502754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A man in his 50s with neurological symptoms during cancer treatment.
    Aanes SG; Nieder C; Prytz J; Odeh F
    Tidsskr Nor Laegeforen; 2018 Oct; 138(17):. PubMed ID: 30378405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversible posterior leukoencephalopathy syndrome (RPLS) associated with Wegener's granulomatosis: a case report and review of the literature].
    Onozawa R; Tsuboi Y; Obata T; Inoue H; Yamada T; Miyake K
    Rinsho Shinkeigaku; 2012; 52(8):567-70. PubMed ID: 22975855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.
    Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K
    Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
    Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
    Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome.
    Li Y; Gor D; Walicki D; Jenny D; Jones D; Barbour P; Castaldo J
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):873-82. PubMed ID: 21703874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.